<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dosing regimens for the treatment of latent tuberculosis* in solid organ transplant candidates and recipients</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dosing regimens for the treatment of latent tuberculosis* in solid organ transplant candidates and recipients</h1>
<div class="graphic"><div class="figure"><div class="ttl">Dosing regimens for the treatment of latent tuberculosis* in solid organ transplant candidates and recipients</div><div class="cntnt"><table cellspacing="0"><colgroup width="25%"></colgroup><colgroup width="75%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1_left"> </td> <td class="subtitle1_left">Nonpregnant adults</td> </tr> <tr class="divider_bottom"> <td><strong>Isoniazid</strong><sup>¶</sup></td> <td>Standard regimen: <ul class="decimal_heading"> <li>300 mg PO daily for 9 months </li> </ul> Alternate regimens: <ul class="decimal_heading"> <li>300 mg PO daily for 6 months </li> <li>900 mg PO twice weekly<sup>Δ</sup> for 6 to 9 months </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Isoniazid and rifapentine</strong><sup>◊</sup></td> <td>Isoniazid (orally once weekly for 12 doses; direct observation is preferred): <ul class="decimal_heading"> <li>15 mg/kg, rounded up to the nearest 50 or 100 mg; 900 mg maximum </li> </ul> Rifapentine (orally once weekly for 3 months; direct observation is preferred): <ul class="decimal_heading"> <li>10 to 14 kg: 300 mg </li> <li>14.1 to 25 kg: 450 mg </li> <li>25.1 to 32 kg: 600 mg </li> <li>32.1 to 49.9 kg: 750 mg </li> <li>&gt;50 kg: 900 mg maximum </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Rifampin</strong><sup>◊</sup></td> <td>600 mg PO daily for 4 months</td> </tr> <tr> <td><strong>Isoniazid and rifampin</strong><sup>◊</sup></td> <td> <p>Isoniazid 300 mg PO daily for 3 months</p> Rifampin 600 mg PO daily for 3 months</td> </tr> </tbody></table></div><div class="graphic_footnotes">PO: by mouth.<br/>* For discussion of clinical approach to selecting a regimen for treatment of latent tuberculosis, refer to the UpToDate topic on treatment of latent tuberculosis infection in solid-organ transplantation.<br/>¶ Pyridoxine supplementation (25 to 50 mg PO daily for adults) should be considered for patients on prolonged isoniazid; this is especially important for patients with conditions that can predispose to neuropathy (including diabetes, uremia, alcoholism, malnutrition, and HIV infection), as well as in the setting of pregnancy and seizure disorders. <br/>Δ Twice-weekly regimens must be administered with directly observed therapy.<br/><font class="lozenge">◊</font> Rifamycins should be avoided or used cautiously for the treatment of latent tuberculosis after transplant with close attention to drug-interactions, dose adjustments for immunosuppressive medications, and monitoring for potential drug toxicities.</div><div class="graphic_reference">Data from: Guidelines for the treatment of latent tuberculosis infection: Recommendations from the national tuberculosis controllers association and CDC, 2020. MMWR 2020: 69:1.</div><div id="graphicVersion">Graphic 65944 Version 30.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
